ArticleNature communications2026
An agent-based platform for simulating the impact of chlamydia vaccine in the US population.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Chlamydia trachomatis (CT) remains the most reported bacterial sexually transmitted infection in the United States (US), underscoring the urgent need for an effective vaccine. An agent-based model calibrated to the US National Survey of Family Growth (NSFG) and National Health and Nutrition Examination Survey (NHANES) datasets was developed and used to study the impact of vaccine on the CT and all-cause pelvic inflammatory disease (PID) burden. The model was further validated against independent epidemiological data. Here we show that a conventional vaccine with 50% efficacy and 60% coverage can achieve a 64.2% [95%CI: 43.0-68.1] reduction in chlamydia prevalence and a 14.3% [95%CI: 10.1-29.4] reduction in the prevalence of women with one or more lifetime episodes of all-cause PID. Prioritizing vaccination among individuals aged 15-24 yielded the greatest impact, even with moderate vaccine performance, highlighting the importance of age-targeted, gender-inclusive strategies. These findings provide quantitative evidence to support the design and implementation of chlamydia vaccination programs and highlight the value of agent-based modeling frameworks for evaluating complex intervention strategies in sexually transmitted infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.